Skip to main content
Log in

Positron emission tomography (PET) is not indicated in the postchemotherapy evaluation of advanced non-seminomatous testicular germ cell tumors

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Daneshmand S, Albers P, Fossa SD, Heidenreich A, Kollmannsberger C, Krege S, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012;62:867–76.

    Article  PubMed  Google Scholar 

  2. Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J Clin Oncol. 2001;19:2647–57.

    CAS  PubMed  Google Scholar 

  3. Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors—prospects for management. World J Urol. 2004;22:132–9.

    Article  CAS  PubMed  Google Scholar 

  4. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Maroto P, García Del Muro X, Sastre J, Isla D. SEOM guidelines: non-seminomatous germ cell cancer (NSGCC). Clin Transl Oncol. 2011;13:565–8.

    Article  PubMed  Google Scholar 

  6. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, et al. 2-18fluoro-deoxy-Dglucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22:1034–9.

    Article  PubMed  Google Scholar 

  7. Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, et al. 2-18fluoro-deoxy-Dglucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.

    Article  CAS  PubMed  Google Scholar 

  8. Aparicio J, Sastre J, Germà JR, Isla D. SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010). Clin Transl Oncol. 2011;13:560–4.

    Article  CAS  PubMed  Google Scholar 

  9. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011;60:304–19.

    Article  PubMed  Google Scholar 

  10. Chung P, Warde P. Contemporary management of stage I and II seminoma. Curr Urol Rep. 2013;14:525–33.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The author J. Aparicio declares no conflict of interest.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to J. Aparicio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aparicio, J., On behalf of the Spanish Germ Cell Cancer Group. Positron emission tomography (PET) is not indicated in the postchemotherapy evaluation of advanced non-seminomatous testicular germ cell tumors. Clin Transl Oncol 16, 509–510 (2014). https://doi.org/10.1007/s12094-014-1161-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1161-2

Keywords

Navigation